Over the past decade, cancer immunotherapy has revolutionized the treatment of cancer with the approval of monoclonal antibodies targeting coinhibitory immune checkpoints, CTLA-4 and PD-1/PD-L1 [26]. The gene discussed is CTLA4; the disease is cancer.